Drugs / Sm29
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06000514 | Jan 2019 → Apr 2022 | cutaneous leishmaniasis | Hospital Universitário Professor Edgard Santos | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sm29 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06000514 ↗ |
| Modality | Protein / enzyme biologic | “The protein, rSm29 of Schistosoma mansoni, down-modulates pro-inflammatory cytokine production.” PMID 39147194 ↗ Aug 2024 |
| Route | Topical | “Sm29 cream twice a day in the ulcer(s), during 20 days” NCT06000514 ↗ |